Elkfork Partners’s Quest Diagnostics DGX Stock Holding History

Elkfork Partners’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$10.7M	Buy	99,960 +9,622	+11%	+$988K	0.26%	77
2019 Q2	$9.2M	Sell	90,338 -9,112	-9%	-$876K	0.22%	96
2019 Q1	$8.94M	Buy	99,450 +26,996	+37%	+$2.34M	0.22%	93
2018 Q4	$6.03M	Buy	72,454 +20,536	+40%	+$1.93M	0.17%	130
2018 Q3	$5.6M	Sell	51,918 -23,154	-31%	-$2.54M	0.13%	159
2018 Q2	$8.25M	Sell	75,072 -13,906	-16%	-$1.45M	0.21%	105
2018 Q1	$8.93M	Sell	88,978 -8,568	-9%	-$878K	0.24%	87
2017 Q4	$9.61M	Sell	97,546 -30,600	-24%	-$2.9M	0.26%	85
2017 Q3	$12M	Sell	128,146 -3,026	-2%	-$321K	0.35%	57
2017 Q2	$14.6M	Buy	131,172 +60,316	+85%	+$6.38M	0.44%	51
2017 Q1	$6.96M	Sell	70,856 -24,616	-26%	-$2.35M	0.21%	96
2016 Q4	$8.77M	Buy	+95,472	New	+$8.23M	0.29%	68

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Elkfork Partners's DGX Position: Q3 2019 in Review

Elkfork Partners increased its Quest Diagnostics (DGX) stake by 11% in Q3 2019, buying an estimated $988K and bringing the position to 99,960 shares worth $10.7M. The position accounts for 0.26% of the portfolio, ranked #77.

Elkfork Partners first reported a position in DGX in Q4 2016 and has held it in 12 quarters since. The position peaked at $14.6M in Q2 2017. 677 funds tracked by Wall St. Rank hold DGX as of Q3 2019.

Elkfork Partners held 99,960 shares of Quest Diagnostics worth $10.7M as of Q3 2019.
Elkfork Partners bought 9,622 Quest Diagnostics shares in Q3 2019, an estimated $988K.
Quest Diagnostics made up 0.26% of Elkfork Partners's portfolio in Q3 2019, its #77 holding.
Elkfork Partners first reported a position in Quest Diagnostics in Q4 2016 and has held it in 12 quarters since.
Elkfork Partners's Quest Diagnostics position peaked at $14.6M in Q2 2017.
677 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.